What is Durvalumab? Durvalumab is an investigational human monoclonal antibody directed against the programmed cell death ligand 1 (PD-L1) protein. Signals from PD-L1 help tumours avoid detection by the immune system. Durvalumab blocks these signals, countering the tumourâs immune-evading tactics. The antibody belongs to an emerging class of immunotherapies commonly referred to as checkpoint inhibitors, because they remove checks the body places on immune activation.
(At the same time, it also causes the kidneys to eliminate potassium.) The body then becomes overloaded with salt and water, and this worsens the heart failure. Spironolactone inhibits the action of aldosterone thereby causing the kidneys to excrete salt and fluid in the urine while retaining potassium. Therefore, spironolactone is classified as a potassium-sparing diuretic, a drug that promotes the output of urine (diuretic) while allowing the kidneys to retain potassium. The FDA approved spironolactone in October 1985.
This medication is also used to treat low potassium levels and conditions in which the body is making too much of a natural chemical (aldosterone). Spironolactone is known as a water pill (potassium-sparing diuretic).OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional.his medication is also used to treat low potassium levels and conditions in which the body is making too much of a natural chemical (aldosterone). Spironolactone is known as a water pill (potassium-sparing diuretic).